{"title":"A new model predicts the best medication for patients with type 2 diabetes mellitus","authors":"Olivia Tysoe","doi":"10.1038/s41574-025-01105-z","DOIUrl":null,"url":null,"abstract":"<p>Many glucose-lowering medications for type 2 diabetes mellitus (T2DM) have varying levels of efficacy in different patients, but it is currently not well understood which criteria should be used to personalize T2DM treatment. A study published in <i>The Lancet</i> has developed a model to predict the efficacy of different T2DM drug classes in reducing glycaemia in patients, based on routinely recorded clinical features.</p><p>The model was developed using primary and secondary care healthcare records from people in the UK aged 18–79 with T2DM, taken from the Clinical Practice Research Datalink (CPRD) database. The primary outcome predicted by the model was a patient’s HbA<sub>1c</sub> level 12 months after drug initiation for each of the five drug classes. The model’s accuracy was validated by comparing predicted and actual HbA<sub>1c</sub> values for the drug classes in three randomized controlled trials.</p>","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"71 1","pages":""},"PeriodicalIF":31.0000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41574-025-01105-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Many glucose-lowering medications for type 2 diabetes mellitus (T2DM) have varying levels of efficacy in different patients, but it is currently not well understood which criteria should be used to personalize T2DM treatment. A study published in The Lancet has developed a model to predict the efficacy of different T2DM drug classes in reducing glycaemia in patients, based on routinely recorded clinical features.
The model was developed using primary and secondary care healthcare records from people in the UK aged 18–79 with T2DM, taken from the Clinical Practice Research Datalink (CPRD) database. The primary outcome predicted by the model was a patient’s HbA1c level 12 months after drug initiation for each of the five drug classes. The model’s accuracy was validated by comparing predicted and actual HbA1c values for the drug classes in three randomized controlled trials.
期刊介绍：
Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
